Testing stronger brain stimulation to improve naming in Alzheimer's disease
Tests stronger tDCS brain stimulation with naming training in people with Alzheimer's disease.
Plain-language title generated from the registry record
Registry title: Investigating if a Stronger tDCS Intensity is More Effective for Improving Naming Ability in People Living With Alzheimer's Disease
Key facts
- Where
- Toronto, CanadaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 50 to 90 with mild to moderate Alzheimer's disease. It tests whether a stronger brain stimulation (tDCS) with naming training helps naming ability.
- Age
- 50 to 90 years
- Sex
- All sexes can join.
- Disease stage
- Mild to moderate Alzheimer's disease.
- Biomarker or test result
- A score between 18 and 25 on the MoCA test. A score on the Cambridge Naming Task at the pre-assessment.
Main reasons for not taking part
- History of stroke or TBI
- Shunts or metal in the body
- History of significant heart disease
- History of alcoholism
- History of drug use
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 90 years old?
Source: NCT05509387, who can take part
Where in Canada
- Baycrest Health SciencesToronto, CanadaContact: Carlos Roncero, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Baycrest
- Trial code
- NCT05509387
- Record updated
- 13 August 2024
- Original description
There is currently little symptomatic therapy for Alzheimer's Disease (AD) and nothing effective for individuals with Frontotemporal dementia (FTD). However, neuromodulation with transcranial direct current stimulation (tDCS) has the potential to be a clinically effective therapy for both AD and FTD. The challenge now is to specify the parameters and conditions under which tDCS is most effective to transition from the laboratory to clinical medicine. tDCS studies typically report significant group effects despite the variability demonstrated among participants, with some showing clear, meaningful improvement, while others only show statistical improvement or none at all. These variable results may be related to the conventional stimulation intensity level of 2mA. The investigators predict that administering tDCS at 4.0 mA, a more significant number of participants would show a meaningful response, and those who improve at 2mA may improve even more from 4.0mA due to having a larger electric field produced. The investigators aim to test this hypothesis in people with Alzheimer's Disease.Read full original descriptionShow less
Investigating if a Stronger tDCS Intensity is More Effective for Improving Naming Ability in People Living With Alzheimer's Disease
There is currently little symptomatic therapy for Alzheimer's Disease (AD) and nothing effective for individuals with Frontotemporal dementia (FTD). However, neuromodulation with transcranial direct current stimulation (tDCS) has the potential to be a clinically effective therapy for both AD and FTD. The challenge now is to specify the parameters and conditions under which tDCS is most effective to transition from the laboratory to clinical medicine. tDCS studies typically report significant group effects despite the variability demonstrated among participants, with some showing clear, meaningful improvement, while others only show statistical improvement or none at all. These variable results may be related to the conventional stimulation intensity level of 2mA. The investigators predict that administering tDCS at 4.0 mA, a more significant number of participants would show a meaningful response, and those who improve at 2mA may improve even more from 4.0mA due to having a larger electric field produced. The investigators aim to test this hypothesis in people with Alzheimer's Disease.
Inclusion: Mild to Moderate AD; Score between 18 and 25 on the MoCA; Score on the Cambridge Naming Task during the pre-assessment.
Exclusion: No history of stroke or TBI; No history of significant heart disease, alcoholism and drug use; No shunts or metal in the body.